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EXPRESSION OF T-CELL DIFFERENTIATION
ANTIGENS ON EFFECTOR CELLS IN
CELL-MEDIATED CYTOTOXICITY IN VITRO
Evidence for Functional Heterogeneity Related to the Surface
Phenotype of T cells*
By H. SHIKU, P. KISIELOW, M. A. BEAN, T. TAKAHASHI, E. A. BOYSE,
H. F. OETTGEN, AND L. J. OLD
(From the Memorial Sloan-Kettering Cancer Center, New York 10021)
Thymus-derived lymphocytes (T cells) participate in cell-mediated immune
reactionsrepresented by delayed hypersensitivity (1), graft-vs-host reactivity (2),
and cell-mediated cytotoxicity (CMC)' (3); and they act as "helpers" in the
production of antibody (4) and in the regulation of immune responses (5).
Effector ("killer") cells concerned in CMC reactions against allogeneic (3),
xenogeneic (6), or syngeneic (7) tumor cells in vitro are characteristically T cells.
Lymphoid cells from nonimmune animals can act as killer cells in the presence of
antibody against target cells (8), but these antibody-dependent killer cells, which bear Fc
and C3 receptors (9), evidently are not T cells. Using a syngeneic Moloney sarcoma
system, some investigators report the killer cells to be thymus dependent (10, 11) and
others not (12) . In CMC against a human bladder carcinoma (13), non-T cells have been
said to play a major role. Thus while there is agreement that T cells can acquire killer
activity, this is not necessarily an exclusive function of T cells as defined by current
criteria .
Using Thy-1 (0) antisera prepared in congenic strains we have confirmed that
killer cells from the peritoneal cavity of hyperimmune alloimmunized mice are
Thy-1+ .2However, the killer population is said to be heterogeneous and to change
* This work was supported by grant CRI-287 of the Cancer Research Institute, Inc., WHO, and
grant CA-08748 of the National Cancer Institute.
`Abbreviations used in this paper: BALB, BALBIc; B6, C57BL/6; CMC, cell-mediated cytotoxic-
ity; EBSS, Earle's balanced salt solution; FBS, fetal bovine serum; NAPC, nonadherent peritoneal
cells; NMS, normal mouse serum; NRS, normal rabbit serum; NTA, natural thymocytotoxic
autoantibody; NTA-RA, NTA-reactive antigen ; PC, peritoneal cells.
z Shiku, H., M. A. Bean, L. J. Old, and H. F. Oettgen. 1975. Cytotoxic reactionsof murine lymph-
oidcellsstudeid with a [3H]prolinemicrocytotoxicity test-J. Natl. CancerInst. In press.
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its physical properties (14, 15) with time after immunization; also, distinguisha-
ble subtypes of T cells cooperate in vitro in generating the CMC killer population
(16) . From this latter standpoint particularly we have been concerned with
characterizing the CMC killer population, represented in our hands by the
nonadherent peritoneal cells (NAPC) of immune mice, in terms of their surface
exhibition of antigens other than Thy-1 that constitute hallmarks of the T cell
(Table I) . In view of growing evidence that T cells are diverse in function (16-19)
we have looked for evidence that they may exhibit concordant diversity in
exhibition of these other surface markers, notably those of the Ly series, which
might serve to identify T-cell subsets with different functions. This present
report is concerned exclusively with the CMC function of T cells.
Our technique for measuringCM C was the [3H]proline microassay whichwe have recently
developed (20) . In this test, adherent target cells are prelabeled with ['H]proline, and
TABLE I
T-Cell Surface Antigens
*Natural thymocytotoxic autoantibody-reactive antigen.
$Mouse specific lymphocyte antigen.
Materials and Methods
radioactivity remaining is measured after CMC has taken place and the monolayer has
been washed free of effector cellsand nonviable target cells. This assaytherefore primarily
monitors the destruction (measured as detachment) of target cells, in contrast to the
Takasugi and Klein assay (21) which is influenced by target cell proliferation as well as
destruction. This [g11 ]proline assay has been valuable in detecting CMC against
alloantigens or tumor antigens or target cells (references 20 and22, andfootnote 2).
Mice (Tables II and III) .
￿
For clarity the formal nomenclature of congenic mouse strains (all of
which in this study were derived at Memorial Sloan-Kettering Cancer Center, New York) has been
simplified from the standard designations listed by Klein (23) as follows: B6/Ly-1 .1 for C57BL/6-Ly-
1°Boy; B6/Ly-2.1 for C57BL/6-Ly-2°Boy; B6/Ly-2.1 Ly-3.1 forC57BL/6-Ly-2°Ly-3°Boy; A/Thy-1.1
for A-Thy-1°/Boy; AKRIH-2° for AKR.B6/1/Boy; B6/H-21 for C57BL/6-H-2'p/Boy; AITL - for
A-Tia°/Boy.
Antisera.
￿
See Table III.
Complement (C)-Dependent Cytotoxicity Assay (Table III).
￿
Modified from GorerandO'Gorman
Antigensystem
(old notation)
:(reference)
Genetic
locus
(chromosome)
Allmice express: Normal cells on whichthese
specificities are expressed
Thy-1(0) :(36,37) 9 Thy-1.1 or Thy-1.2 Thymocytes andotherTcells,
brain, andepidermalcells
Ly-1 (Ly-A):(35) 19 Ly-1 .1 or Ly-1.2
Ly-2 (Ly-B):(35) 6 closely Ly-2 .1 or Ly-2.2 Thymocytes andotherTcells
Ly-3 (Ly-C):(32) ~ linked Ly-3.1 or Ly-3.2
TL (38) 17 no TL,TL.2 or TL. 1,2,3 Thymocytes only
NTA-RA*:(27) - NTA-RA Thymocytes andotherTcells,
andbrain
MSLAt:(39) - MSLA Thymocytes andotherTcellsSHIKU, KISIELOW, BEAN, TAKAHASHI, BOYSE, OETTGEN, AND OLD
* Congenic strains.
TABLE II
Mice Used, and Their T-Cell Antigen Phenotypes
TABLE III
Antisera
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*Reciprocal of dilution giving 50% of maximal percentage lysis.
$Congenic strains.
§Absorbed with syngeneic thymocytes to remove autoantibody.
11 Kindly provided by Doctors R. C. Mellors and T. Yoshiki, Hospital for Special Surgery, Cornell
University Medical College, New York.
(24, 25): 0.05 ml vol of (a) cells (5 x 10°/ml), (b) antiserum (serially diluted), and (c) C; incubated
together in 10 x 15-mm glasstubes for 45 min at 37°C; proportion of dead cells determined by adding
0.1 ml of 0.16% freshlyprepared trypan blue to each tube. In early experiments selected rabbit serum
(diluted 1/15) was used as the C source; later, rabbit serum absorbed with mouse cells in thepresence
of EDTA (26) was preferred (diluted 1/6); for anti-MSLA tests, selected guinea pig serum (diluted
1/3) was used instead. In titrating the natural thymocytotoxic autoantibody (NTA) of NZB mice we
washed the presensitized cells before adding C, because this enhances the titer (27).
Cultured Target Monolayer Cells.
￿
Cultures from A andC57BL/6 (B6) mouseembryos, and from
two BALB/c (BALB) methylcholanthrene-induced sarcomas (Meth A or Meth 113, which gave
similar results), were used as target cells between their 4th to 10th passages in vitro, as described.z
[3H)Proline CMC Microassay (references 20 and 22, and footnote 2). Briefly, 1,000 [3H]proline-
Serum: anti- Production
Cytotoxicity
On thymocytes
assaytiter*
On immune
NAPC
Dilution for
CMCassay
Thy-1.1 (B6 x A)F, anti-A/Thy-1.1$ 2,500 160 20
thymocytes
Thy-1.2 (A/Thy-1.1 x AKR/H-2°$) F, 10,240 320 20
anti-A spontaneous leukemia
ASLI
Ly-1.1 (BALB x B6)F, anti-B6/Ly- 2,560 2,560 20
1.1$thymocytes
Ly-1.2§ C3H anti-CEthymocytes 160 80-160 20
Ly-2.1 B6/I3-2" $ anti-CE thymocytes 1,600 320 20
Ly-2.2 (C3H x B6/Ly-2.1$)F, anti-B6 640 80 20
leukemia ERLD
Ly-3.2§ C58anti-CEthymocytes 160 40 15
TL. 1, 2, 3§ (A/TL- $ x B6)F, anti-ASLl 5,120 negative 20
NTA-RA 11 Olduntreated NZB mice 256-512 20 5
MSLA Rabbit anti-ASL1 absorbed in 160 160 15
vivo in A mice
Mousestrain Thy-1 Ly-1 Ly-2 Ly-3 TL
B6 2 2 2 2 Negative
B6/Ly-1.1 2 1 2 2 Negative
B6/Ly-2.1 2 2 1 2 Negative
B6/Ly-2.1 Ly-3.1* 2 2 1 1 Negative
A 2 2 2 2 1,2,3
A/Thy-1.1* 1 2 2 2 1,2,3230
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labeled target cells were seeded in each well of a Microplate II (no. 3040, Falcon Plastics, Div. of
BioQuest, Oxnard, Calif.). On the following day, 1 x 105 effector cells (NAPC), obtained and pre-
treated as described below, were added. After incubation (humidified 5%p CO, in air at 37'C for 12 to
20 h) unattached dead target cells and effector cells were washed away with 37'C phosphate-buffered
saline with 5% fetal bovine serum (FBS) . After processing,' the residual radioactivity (counts per
minute) of cells attached to each well was measured, indicating the numbers of viable target cells
remaining. Protocol: four replicates per sample; every effector suspension was tested on syngeneic
control target monolayer(s) as well as on the cognate target monolayer(s). The "percent CMC" is
calculated as [1 - (a)/(b) ] x 100, where (a) = counts per minute of target monolayer exposed to
NAPC from "immune" donors, and (b) = counts per minute "standard," i.e., of same target mono-
layer treated with NAPC from "nonimmune" donors.
Immunization of Donor Mice for CMC Assays. Mice were immunized weekly four times by
intraperitoneal (i.p.) inoculations of 5 x 108 allogeneic spleen cells; peritoneal cells (PC) were
harvested 3 days later.' Nonimmune PC were obtained from mice inoculated with syngeneic spleen
cells according to the same schedule. In certain experiments (Table VIII) PC were harvested 5 days
after a single i.p. inoculation of 100 x 108 allogeneic spleen cells.' The donor to target cell com-
binations used all involved H-2 incompatibility and are apparent from the abbreviated notations
in the table ("B6 anti-BALB", etc.) .
Detection of T-Cell Surface Antigens on Killer Cells by Pretreatment of NAPC with Selected
T-Cell Antisera. NAPC from immune andnonimmune donors (see preceding section) were washed
twice in Earle's balanced salt solution (EBSS) with 100 U/ml ofpenicillin, 100 ug/ml of streptomycin,
and 2.5% FBS (56'C/30 min); resuspended in CMC-assay-medium and incubated (3-5 x 108
cells/ml) in T-60 glass flasks (5% C02 in air) at 37°C for 1 h. The CMC-assay-medium was Eagle's
minimal essential medium (MEM) supplemented with 2 mM glutamine, 1% nonessential amino
acids, 100 U/ml of penicillin, 100 pg/ml of streptomycin, 10% FBS (56'C/30 min), and 5 x 10-5 M
2-mercaptoethanol. Unattached cells were transferred to new flasks and incubated for a further hour
under the same conditions. The unattached cells (NAPC) were washed once and resuspended (5 x
108 cells/ml) in EBSS with supplements as above and 5 x 10-5 M 2-mercaptoethanol which helps to
maintain functional lymphocyte activity (28) . Aliquots of the cells were then exposed to three or more
selected antisera under conditions similar to the standard C-dependent cytotoxicity assay (see
above) ; i.e. one volume of cell suspension, added to one volume of antiserum (dilutions shown in
Table III and VII), and one volume of C; C preparation as described for C-dependent cytotoxicity as-
say (above); incubated in siliconized glass tubes, with occasional shaking, for 45 min, in 5% C02 in air.
Each tube was then sampled for the viability counts (trypan blue) which constitute the data for
"% cells lysed" given in Table X. Meanwhile the remainders of the NAPC suspensions were washed
twice andresuspended (1 x 108 viable cells/ml) in CMC-assay-medium; 0.1 ml wasadded to each well
of the Microtest plate II already seeded with ['H]proline prelabeled target cells ( ['Hlproline CMC
microassay, see above). The"percent reduction of CMC" (Tables IV-VIII, and X) resulting from pre-
treatment of the NAPC population was calculated as [1 - (a)/(b) ] x 100, where (a) = "percent CMC"
(see above) of NAPC pretreated with test antiserum and C, and (b) = percent CMC of NAPC pre-
treated with control serum plus C. The "percent inhibition of CMC" (Table IX) is calculated in an
identical fashion but refers to the change in CMC of effector cells in the continued presence of anti-
sera without C. The control serum was sometimes normal mouse (NMS) or normal rabbit serum
(NRS) but more usually and whenever possible the "reciprocal" immune serum, illustrated by anti-
Ly-1.1 in place of the cognate anti-Ly-1 .2 in Table VI.
Results
Pretreatment of Immune NAPC Population with Various T-Cell Antisera;
Effect on Subsequent CMC Capacity
ANTI-Thy-1. Table IV shows in detail two experiments (others are summa-
rized in Table X) in which elimination of Thy-1+ cells by Thy-1 antiserum and C
abolished all CMC. The main evidence for specificity is the control in which use
of reciprocal Thy-1 antiserum (anti-Thy-1.1 in place of anti-Thy-1 .2) gave only aslight reduction ofCMC as compared with the "diluent only" control (e.g., cpm
1,069 compared with 889 in exp. 1 in Table IV) such as might be expected from
slight toxicity from the addition ofthe C source above. The last entry in Table IV
is "bystander control"showing that lysis of irrelevant cells (Thy-1 .1 thymocytes
by anti-Thy-1.1) did not nonspecifically depress the CMC ofthe Thy-1.2 effector
cells. The percent NAPC lysed by Thy-1 antiserum during pretreatment in these
experiments is shown in Table X.
ANTI-MSLA, ANTI-TL, AND NTA .
￿
Results with these three systems are illustrated
in detail in Table V (summary of all results in Table X). Pretreatment with
* With C also in the case of NAPC being exposed to antiserum; this applies to pre-treatment in experiments shown
in all other tables except IX.
$ Control for "bystander effects:" Lysis of extraneous Thy-1 .1 thymocytes by Thy-1.1 antiserum did not interfere
with CMC of Thy-1.2 NAPC.
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TABLE IV
Thy-1 Antigen on Killer Cells
Exp. 1 (B6 anti-BALB system)
￿
Exp. 2 (A anti-B6 system)
TABLE V
MSLA, TL, and NTA-RA on Killer Cells
Cells (NAPC) treament cpm (target
cells)
CMC Reduction
ofCMC
cpm (target
cells)
CMC Reduction
ofCMC
B6 anti-BALB system
MSLA system
Nonimmune Diluent only 6,804 0 4,708 0
Immune Diluentonly 901 87 1,278 73
Immune Anti-MSLA 6,331 7 92 4,054 14 81
Immune NRS 1,087 84 Standard 1,271 73 Standard
A anti-B6 system
TL system
Nonimmune Diluent only 3,991 0 2,492 0
Immune Diluent only 326 92 398 84
Immune Anti-TL1,2,3 415 90 2 727 71 9
Immune NMS 356 91 Standard 557 78 Standard
B6 anti-BALB system
NTA-RA (NZB) system
Nonimmune Diluent only 2,803 0 2,552 0
Immune Diluent only 1,313 53 302 88
Immune NTA 2,353 16 63 1,675 34 60
Immune NMS 1,556 44 Standard 371 85 Standard
Cells (NAPC) Pretreatment* cpm
(target
cells)
CMC
Reduction
ofCMC
cpm (target
cells)
CMC Reduction
of CMC
Nonimmune Diluent only 2,639 0 3,991 0
Immune Diluent only 889 66 326 92
Immune Anti-Thy-1.2 2,646 0 100 4,024 -1 101
Immune Anti-Thy-1.1 1,069 59 Standard 390 90 Standard
Immune, plus Thy-1.1 Anti-Thy-1.1 1,074 59 0 418 89 1
thymocytes$232
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anti-TL gave no suppression of CMC; NTA gave incomplete suppression; and
anti-MSLA gave stronger suppression, approaching the level of suppression by
anti-Thy-1.
ANTI-Ly-1, ANTI-Ly-2, AND ANTI-Ly-3.
￿
Representative results are illustrated in
detail in Table VI, and again the results of all experiments are summarized in
Table X, where the proportions of cells lysed by the antisera are also shown. The
salient feature of these results is that the proportion of cells lysed by the various
antisera during pretreatment is not concordant with the effect on suppression of
CMC. Two extremes are illustrated in Table VI : (a) no CMC suppression by
TABLE VI
Ly Antigens on Killer Cells
anti-Ly-1.2, although 74% (mean) of Thy-1+ cells had been lysed (Table X), as
compared with (b) 70% CMC suppression by anti-Ly-3.2 (Table VI) which lysed
a smaller proportion of the T cells (54% ; Table X) . It must be emphasized that
such results were obtained repeatedly with concurrent CMC tests carried out on
aliquots of the same NAPC preparation pretreated with each of these two
antisera, so the danger of variation from experiment to experiment is not a factor
that need be considered.
Use of Thy-1 and Ly Congenic MouseStrains (Table II) in FurtherExploration
of the Killer Cell Phenotype (Table VII) . The special value of congenic strains
differing for T-cell-specific surface markers in the context of this study is that
Cells (NAPC) Pretreatment cpm
cells)
CMC Reduction
of CMC
cpm
(tar
get
cells)
CMC Reduction on
of CMC
B6 anti-BALB system
Ly-1 system
Nonimmune Diluentonly 16,277 0 4,977 0
Immune Diluentonly 2,697 83 1,213 76
Immune Anti-Ly-1.2 2,938 82 -2 1,617 67 13
Immune Anti-Ly-1.1 3,300 80 Standard 1,096 78 Standard
B6 anti-BALB system
Ly-2 system
Non-immune Diluentonly 2,203 0 7,501 0
Immune Diluentonly 528 76 1,072 86
Immune Anti-Ly-2.2 1,552 30 60 5,749 23 74
Immune Anti-Ly-2.1 565 74 Standard 801 89 Standard
B6 anti-BALB system
Ly-3 system
Nonimmune Diluentonly 2,826 0 7,501 0
Immune Diluentonly 330 88 1,072 86
Immune Anti-Ly-3.2 2,108 25 70 7,044 6 93
Immune NMS 409 85 Standard 1,255 83 Standard*Dilution of antisera.
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TABLE VII
Use of Thy-1 and Ly Congenic Strains in Further Study of the
Phenotype of the Killer Cells
comparative tests on the alternative allelic product in each system can be carried
out on a uniform genetic background, e.g., anti-Ly-1.2 acting on B6 killer cells
(Ly-1.2) as compared with anti-Ly-1.1 acting on B6/Ly-1.1 killer cells (congenic
with B6). In the case of Thy-1, this "reciprocal system" (anti-Thy-1.1 acting on
A/Thy-1.1 cells) gave essentially the same results, i.e. virtually complete
suppression of CMC (Table VII), as anti-Thy-1.2 acting on A strain cells (Table
IV).
Results from the Ly congenic lines are especially important because one might
infer from data based only on B6 killer cells (Table VI) that the phenotype
Ly-1f :Ly-2/Ly-3T is typical of all mouse NAPC killer cells. In fact the
comparable results with the Ly congenic cells raise doubts on this point because
CMC suppression by anti-Ly-1.1 was considerable and CMC suppression by
anti-Ly-2.1 was only slight (Table VII), in contrast with the Ly-1 .2 and Ly-2 .2
alternatives (Table VI). However, regarding the CMC suppression by an-
Cells (NAPC) Pretreatment cpm (target cells) CMC Reduction
of CMC
A/Thy-1.1 (congenic) anti-B6system
Nonimmune Diluentonly 4,571 0
Immune Diluentonly 327 93
Immune Anti-Thy-1 .1 3,860 16 83
Immune Anti-Thy-1 .2 304 93 Standard
B6/Ly-1.1 (congenic) anti-BALB system
Nonimmune Diluentonly 4,718 0
Immune Diluentonly 1,541 67
Immune Anti-Ly-1.1 (1/20)* 3,216 32 48
Immune Anti-Ly-1.1 (1/160) 3,229 32 48
Immune Anti-Ly-1.1 (1/320) 2,507 47 23
Immune Anti-Ly-1.1 (1/640) 1,920 59 3
Immune Anti-Ly-1.2 (1/20) 1,832 61 Standard
B6/Ly-2.1 (congenic) anti-BALB system
Nonimmune Diluentonly 18,224 0
Immune Diluentonly 5,884 68
Immune Anti-Ly-2.1 7,342 60 15
Immune Anti-Ly-2.2 5,360 71 Standard
B6/Ly-2.1 Ly-3.1 (congenic) anti-BALB system
Nonimmune Diluentonly 4,198 0
Immune Diluent only 429 90
Immune Anti-Ly-2.1 841 80 8
Immune Anti-Ly-2.2 551 87 Standard
Immune NMS 552 87 0
Immune Anti-Ly-3.2 442 89 Standard234
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ti-Ly-1.1 it is noteworthy that the cytotoxic titer of this antiserum is exception-
ally high (1/2,560; Table III) although its titer in regard to CMC suppression is
much lower. Therefore at critical dilutions there is a high cytolytic effect with
little or no CMC suppression. (These discrepancies are further considered below;
see Discussion).
A few general comments : It is unfortunate that anti-Ly-3.1 serum was not
available at the time of these experiments. However, the completely negative
result with Ly-3.2 antiserum (on Ly-3 .1 cells) is worth emphasis as an excellent
control for serological specificity.
Results with Singly Immunized NAPC Donors (Table VIII). We wished to
determine whether the surface antigen phenotype of killer cells generated at an
Thy-1 and Ly Antigens Phenotype of Killer Cells from Singly Immunized Mice
TABLE VIII
early stage of immunization would differ from that of hyperimmune donors, i.e.
whether there might be some qualitative change in CMC-active T cells with
progressive immunization, of the sort that characterizes the progression of
antibody responses (29) . We knew from our own experience that CMC activity of
PC as a whole is augmented by repeated immunization.z But Table VIII gives
no evidence for a qualitative change, because the comparative CMC suppression
by a panel of Ly sera was the same in singly immunized donors as in multiply
immunized donors (compare Table VIII with Tables VI and VII).
Lack of CMCInhibition by T-Cell Antisera in theAbsenceof C (Table IX).
￿
If
it were the case that any of the T-cell surface components identified by T-cell
antisera mediated some essential eventin CMC, such as recognition of antigen, it
might be expected that the cognate antisera would blockthe CMC ofviable killer
cells without the need for ensuing C-dependent lysis. We found no evidence for
this because pretreatment of NAPC with any of the several T-cell antisera (or
Cells(NAPC) Pretreatment cpm
(target cells) CMC Reduction
ofCMC
B6 anti-BALB system
Nonimmune Diluentonly 3282 0
Immune Diluentonly 1641 50
Immune Anti-Thy-1 .2 2582 21 67
Immune Anti-Thy-1.1 1171 64 Standard
Immune Anti-Ly-1.2 1157 65 -7
Immune Anti-Ly-1.1 1269 61 Standard
Immune Anti-Ly-2.2 2362 28 56
Immune Anti-Ly-2.1 1199 63 Standard
Immune Anti-Ly-3.2 2574 21 66
Immune NMS 1189 64 Standard
B6/Ly-1.1 (congenic) anti-BALB system
Nonimmune Diluent only 1122 0
Immune Diluent only 612 45
Immune Anti-Ly-1.1 937 16 67
Immune Anti-Ly-1.2 558 50 StandardSHIKU, KISIELOW, BEAN, TAKAHASHI, BOYSE, OETTGEN, AND OLD
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TABLE IX
CMC is not Inhibited by Exposure of Killer Population to
Various Alloantisera in the Absence of C
* 136 anti-BALB system; preincubated (10' cells/ml), for 1 h at 4°C with antiserum 1/5; cells
transferred to wells of CMC assay plate without washing (therefore final concentration of antibody
during CMC assay was 1/10).
fIncubation period for CMC assay.
§ (1) DBA/2 anti-C57131, leukemia EL4 and (2) B6/H-2" anti-C57BL leukemia EL4.
H-2 antisera) listed in Table IX, in the absence of C, produced no CMC
suppression during either a 3 or 15 h CMC assay period, despite the fact that the
concentrations of antisera used were higher than standard and that the antisera
remained in the medium throughout the CMC assay.
Discussion
The results are summarized in Table X, to which we refer in the following
discussion . Certain features need little comment. The ability of some T-cell-
specific cytotoxic antisera (to Thy-1.1, Thy-1.2, and MSLA) to abolish virtually
all CMC confirms that T cells are essential to this function of the immune NAPC
population, regardless of whether some cells other than T cells may also be
involved. The entirely negative results with anti-TL might be anticipated from
the fact that TL is expressed exclusively on thymocytes and not on functional
peripheral T cells. The intermediate suppression of CMC activity by NTA is not
particularly informative because this is not a strictly defined antigenic system in
the sense of Thy-1, TL, and the Ly series .
Undoubtedly greater interest attaches to the different degrees of CMC
suppression observed with various Ly antisera, because of the possibility that
functional heterogeneity of the T-cell population, arising from progressive,
alternative, or divergent differentiation, might be reflected by different profiles
of surface exhibition of Ly antigens. Our study provides some pointers in that
direction.
Such an interpretation of results with the Ly antisera depends on comparing:
Cells*
(NAPC)
Antiserum cpm
(target
cells)
CMC
Inhibition
of CMC
cpm
(target
cells)
CMC
Inhibition
of CMC
Nonimmune Diluentonly 4,188 3,746
Immune Diluent only 818 80 397 89
Immune Anti-H-2° (14 540 87 -5 424 89 0
Immune Anti-H-2° (2) § 663 84 -1 441 88 1
Immune Anti-Thy-1 .2 751 83 1 329 91 -2
Immune Anti-Ly-1.2 723 82 1 392 89 0
Immune Anti-Ly-2.2 843 80 4 406 89 0
Immune Anti-Ly-3.2 508 88 -6 278 93 -4
Immune NMS 710 83 Standard 404 89 Standard236
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TABLE X
Summary*
* Based on Tables IV to VIII and other experiments using the same protocols.
(a) the proportion of T cells lysed by a particular Ly antiserum, with (b) the
CMC capacity of the residual population. We shall make the reasonable
assumption that all Ly-bearing cells belong to the T-cell (Thy-1+) lineage. On
this basis it is apparent that the proportion of T cells lysed by a given Ly
antiserum does not regularly correspond with the degree towhich CMC capacity
is lost (Fig. 1). The extremes are represented by: (a) Ly-1 .2 antiserum-74%
T cells destroyed without loss of CMC capacity, and (b) Ly-3.2-antiserum-only
54% T cells destroyed, but with 77% loss of CMC. This implies that most of the
26% CMC-competent cells remaining after anti-Ly-1.2 lysis are susceptible to
lysis by Ly-3.2 antiserum. Hence the T-cell members of the NAPC population
must be heterogeneous, and the NAPC CMC-effector cell population ofB6 mice
has the phenotype Ly-1 .2 f:Ly-2.2/Ly-3.2T.3
Can it be inferred from this thatthe killer population phenotype characteristic
of all mice is Ly-1f :Ly-2/Ly-3T? On the present data, which were deliberately
restricted to repeated CMC tests with asingle dilution ofeach antiserum (to keep
the study within manageable limits) it is not possible to give a definite answer .
But it seems likely that Ly classification will become increasingly important in
the study of T-cell subsets, so it may be timely to comment further on the Ly
systems in this context," and to speculate further about the interpretation ofour
s Sullivan, Berke and Amos mention similar findings on Ly-1.2 and Ly-2.2 in a footnote to their
report in Transplantation 16:388, 1973.
Having undertaken in this discussion to deal briefly in ageneral waywith the Ly systems, we add
the following points about them to complete the account. In addition to the new Ly-5 system noted
above, other unanalyzed serological reactions on lymphocytes point to the existence of yet other T-cell
Ly systems that remain to be delineated . So the Ly class of T-cell antigens, i.e . of antigens
represented exclusively and invariably on mouse T cells, is evidently extensive, and involves several
distinct genetic loci. It is apeculiarity of Ly systems that immunization between congenic Ly strains
sometimes completely fails to give rise to the Ly antibody sought; in each case in Table III (where
antiserum preparation is summarized) when the immunization protocol shown does not involve use of
Sera: anti-
Immune NAPC lysed during
with antibody and
Mean % As
(range)
incubation
C
%Thy-1+
cells
Reduction of CMC (%) : mean
(individual tests)
Thy-1 .1 45(45) 83(83)
Thy-1.2 39(25-48) 100(101,100,100)
Ly-1 .1 33(26-40) 85 58 (48,69)
Ly-1 .2 29(22-33) 74 4(-4,-3,11,13)
Ly-2 .1 8(6-12) 20 11 (8,13,15)
Ly-2.2 23(10-31) 60 63 (48,60,60,74,75)
Ly-3 .2 21(12-28) 54 77 (63,70,80,93)
TL. 1,2,3 <5 <10 5(2,9)
NTA-RA 39(34-43) 100 62 (60,63)
MSLA 36(33-41) 92 86 (81,92)SHIKU, KISIELOW, BEAN, TAKAHASHI, BOYSE, OETTGEN, AND OLD
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Fig. 1. Summary: Discordance of cytolytic and CMC suppressive capacity of different T-cell
antisera (based on Table X) .
initial study. Undoubtedly the issues will automatically become much clearer
when results of corresponding studies, using the same Ly antisera but different
T-cell functional criteria, become available.
To simplify matters we can regard Ly-2 and Ly-3 as a single system
(Ly-2/Ly-3) on the grounds that although they must refer to different mutable
sites they are so closely linked that no crossing-over has been observed among
several hundred segregants ; moreover there is mutual interference between Ly-2
and Ly-3 antibodies competing for sites on the thymocyte surface (32) ; therefore
Ly-2 and Ly-3 antigens must be closely adjacent, perhaps even on the same
molecule. In keeping with this, the results with Ly-2.2 and Ly-3.2 antisera (Table
X and Fig. 1) were very similar. (A third Ly system, Ly-5, is already well-defined'
but has not so far been employed in any functional study.)
First, these two systems show a possibly noteworthy difference in regard to the
sensitivity of peripheral T cells to lysis by the respective antisera (thymocytes by
contrast are virtually all sensitive to lysis by all Ly antisera under optimal
conditions). In the case of Ly-1 antisera, the end point titers against both cell
types (thymocytes and peripheral T cells) are roughly the same, but with
Ly-2/Ly-3 antisera the titers against peripheral T cells are considerably lower
than against thymocytes (Table III, and see confirmatory data in reference 33).
Therefore by this criterion alone the two systems appear to differ.
The reason for concluding that the CMC cell may characteristically be low in
Ly-1 antigen is that 74% of T cells can be lysed by anti-Ly-1.2 serum with
congenic partners, this is due to the failure of "congenic immunization" to give rise to the particular
Ly antibody. Of several possible explanations, control by Ir genes or inadvertent induction of
chimerism or some other variety of tolerance are less likely, on evidence available, than some
requirement for additional antigenicity of the sort described by Schierman and McBride (30) in
immunization with chicken red blood cells (double incompatibility giving rise to antibody where
single incompatibility will not) . A second peculiarity of immunizations involving only Ly differences,
whether in the congenic situation or not, is that large amounts of thymocyte autoantibody are often
formed (31). This is more characteristic of some Ly immunizations than that of others (Table III) .
6 Komuro, K., K. Itakura, E. A. Boyse, and M. John. 1974. Ly-5; a new T-lymphocyte antigen
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virtually no lowering of CMC (Table X and Fig. 1). But on the other hand,
anti-Ly-1.1 used against B6/Ly-1.1 congenic cells eliminated 85% of T cells with
substantial reduction of CMC (58%). So either there are no general profiles of
representation of Ly systems on T cells of different functions, or else the
substantial CMC suppression by anti-Ly-1.1, in contrast to anti-Ly-1.2, has
another explanation. In favor of the latter view is that anti-Ly-1.1 lysed a high
population of T cells (85%), and that it had the highest titer of all Ly antiserum.
As our protocol called for use of the Ly-1.1 and Ly-1 .2 antisera at the same
dilution (1:20) it may be that the very high relative concentration of Ly-1.1
antibody resulted in lysis of cells bearing only small amounts of Ly-1 .1, or that a
contaminant non-Ly-1 antibody was involved; the use of a congenic system for
preparing Ly-1 .1 antiserum does not necessarily exclude this because the Ly
congenic strains differ for loci linked to Ly which are responsible for
histoincompatibility, although these have not been shown to induce cytotoxic
antibody (34) . Either could account for the higher lytic titer of anti-Ly-1.1 (Table
111) in comparison with its titer in CMC suppression (Table VII). In short, it may
be more significant under these conditions that the anti-Ly-1.2 was negative in
CMC suppression than that the Ly-1 .1 antiserum was substantially positive, i.e.,
the former result cannot be otherwise interpreted but the latter can. This
question requires more detailed study.
Secondly, if the killer population is Ly-2/Ly-3 rich, why was anti-Ly-2.1 so
weak in CMC suppression? Here we can only point out that for reasons unknown
anti-Ly-2.1 lyses a far lower proportion of NAPC than any other Ly antiserum
(only 8%), corresponding to its low representation on peripheral T cells according
to quantitative absorption (35) ; yet despite this it was capable of marginal
suppression of CMC (11%).
To reiterate our conclusions: The contention that different T-cell subsets
among the NAPC population of B6 mice are distinguishable by the different
effects of Ly-1 .2 and Ly-2.2/Ly-3.2 antisera is adequately substantiated by our
data, and the phenotype of the killer cell here is undoubtedlyLy-1 .2J :Ly-2.2/Ly-
3.2T. Whether the phenotype of the NAPC killer cells of the mouse generally will
prove to be Ly-1f :Ly-2/Ly-3T is a provocative hypothesis to be studied further.
Summary
The cell-mediated cytotoxicity (CMC) of nonadherent cells from the peritoneal
cavity (NAPC) of alloimmunized mice can be measured by the [3H]proline
microassay . The exhibition of thymus-derived (T) cell antigens on these killer
cells was studied by incubating them with the relevant T-cell antisera and
complement (C), under optimal conditions for lysis, before performance of the
CMC assay.
Underthese conditions, the following T-cell antigens were demonstrable on the
killer population in terms of percent reduction in CMC by the respective
antisera: (a) Thy-1.1 (83%) and Thy-1.2 (100%), (b) MSLA (86%), (c) NTA-RA
(a T-cell antigen recognized by naturally occurring autoantibody of NZB mice)
(62%), (d) Ly-1 .1 (58%), (e) Ly-2 .1 (11%; considered a marginal result) andSHIKU, KISIELOW, BEAN, TAKAHASHI, BOYSE, OETTGEN, AND OLD
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Ly-2.2 (63%), and (f) Ly-3 .2 (77%) . The following were not demonstrable: (g) TL,
and (h) Ly-1.2 . (i) The antigen Ly-3.1 was not studied.
Omission of C deprived all T-cell antisera tested of their capacity to suppress
CMC, indicating that the cell components recognized by such antisera may
perform no direct function in CMC . On the assumption that all Ly+ cells are
Thy-1+, it is clear that the T-cell members of the immune NAPC population
must be heterogeneous. This follows from the fact that the proportions of T cells
lysed by different Ly antisera did not correspond with ensuing degree of loss of
CMC capacity. The extremes were represented by anti-Ly-1 .2 (74% Thy-1+ cells
lysed, but no reduction in CMC) and Ly-3.2 (54% Thy-1+ cells lysed, with 77%
reduction in CMC) .
From this initial survey it appears that the C57BL/6 mice killer T-cell
population active in CMC in vitro is relatively rich in surface antigens of the
Ly-2/Ly-3 category and relatively poor in representation of the Ly-1 surface
antigens. It remains to be seen whether this killer cell phenotype, poor in Ly-1
and rich in Ly-2/Ly-3, is characteristic of the mouse generally. From these results
it appears that subsets of T cells with different immunological functions may
exhibit qualitative or quantitative differences in surface antigens specified by
different Ly loci; this will be easier to assess in the future when the results of
experiments with the same Ly antisera but dealing with T-cell functions other
than CMC become available.
Mrs. S. Maisel, Miss J. Feld, and Mrs. M. Newman provided excellent technical assistance.
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